Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology

Canakinumab is an anti-interleukin-1β monoclonal antibody approved for use in a range of immune-related disorders. During the clinical investigation (CANTOS trial) for prevention of cardiovascular complications, therapy was linked to a reduction in both the occurrence and mortality of lung cancer. T...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2022-09, Vol.127 (5), p.785-787
Main Authors: Lythgoe, Mark P., Prasad, Vinay
Format: Article
Language:English
Subjects:
692/4028/67
692/4028/67/1612/1350
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Chemotherapy
Clinical trials
Cytokines
Cytotoxicity
Drug Resistance
Drugs
Epidemiology
FDA approval
IL-1β
Immunotherapy
Infections
Lung cancer
Metastasis
Molecular Medicine
Monoclonal antibodies
Non-small cell lung carcinoma
Oncology
Patients
Perspective
Regulatory approval
Small cell lung carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canakinumab is an anti-interleukin-1β monoclonal antibody approved for use in a range of immune-related disorders. During the clinical investigation (CANTOS trial) for prevention of cardiovascular complications, therapy was linked to a reduction in both the occurrence and mortality of lung cancer. This unexpected observation fuelled the rapid initiation of four large clinical trials to evaluate potential anticancer efficacy (in combination with chemotherapy and/or immunotherapy), before fully validating these observations in a dedicated study. The first two trials (CANOPY-1 and 2) have now been reported and have both have failed to meet their primary efficacy endpoints. In this article, we explore the scientific and clinical rationale behind the development of canakinumab in oncology, the repurposing approach utilised and implications this may have for the wider drug repurposing field in the development of new cancer medicines.
ISSN:0007-0920
1532-1827
DOI:10.1038/s41416-022-01893-5